{"Literature Review": "The fibroblast growth factor (FGF) family, encompassing 22 structurally related proteins, has been identified as pivotal in regulating cell proliferation, differentiation, development, and metabolism. Among these, FGF1, FGF4, FGF19, and FGF21 have emerged as critical regulators of whole-body energy homeostasis, glucose/lipid metabolism, and insulin sensitivity, making them promising targets for the treatment of obesity-related metabolic complications (Itoh & Ornitz, 2008). Preclinical studies have consistently highlighted the therapeutic potential of these FGFs in addressing obesity, diabetes, dyslipidemia, and nonalcoholic steatohepatitis (NASH) (Kharitonenkov et al., 2005; Kurosu et al., 2007). The development of genetically engineered FGF19 and FGF21 analogs, with enhanced pharmacodynamic and pharmacokinetic properties, has marked a significant advancement in this field. These analogs have progressed through various stages of clinical trials, demonstrating efficacy in alleviating hepatic steatosis, steatohepatitis, and liver fibrosis in biopsy-confirmed NASH patients (Harrison et al., 2018; Sanyal et al., 2019). However, the antidiabetic and antiobesity effects of these FGF analogs have been observed to be mild and vary significantly across different clinical trials, indicating the complexity of translating preclinical findings into clinical benefits (Gaich et al., 2013; Charles et al., 2019). This variability underscores the challenges in the clinical implementation of FGF-based therapies, including the need for optimized dosing regimens, improved delivery systems, and a deeper understanding of the mechanisms underlying the metabolic effects of FGFs (Adams et al., 2012; Talukdar et al., 2016). Despite these hurdles, the ongoing development of agonistic antibodies targeting FGF receptors offers a promising avenue for enhancing the therapeutic efficacy of FGF-based treatments (Wu et al., 2011; Foltz et al., 2012). In conclusion, while FGF-based pharmacotherapies hold significant promise for the treatment of obesity-related metabolic complications, overcoming the challenges in clinical implementation will be crucial for realizing their full therapeutic potential.", "References": [{"title": "Evolution of the Fgf and Fgfr gene families", "authors": "Itoh, Nobuyuki, Ornitz, David M.", "journal": "Trends in Genetics", "year": "2008", "volumes": "24", "first page": "31", "last page": "39", "DOI": "10.1016/j.tig.2007.10.002"}, {"title": "FGF-21 as a novel metabolic regulator", "authors": "Kharitonenkov, Alexei, Shiyanova, Tatiana L., Koester, Anja, Ford, Amy M., Micanovic, Radmila, Galbreath, Elizabeth J., Sandusky, George E., Cunningham, Brian C., Adams, Andrew C.", "journal": "Journal of Clinical Investigation", "year": "2005", "volumes": "115", "first page": "1627", "last page": "1635", "DOI": "10.1172/JCI23606"}, {"title": "Regulation of fibroblast growth factor-23 signaling by klotho", "authors": "Kurosu, Hiroshi, Ogawa, Yoshihiro, Miyoshi, Masaki, Yamamoto, Masaya, Nandi, Animesh, Rosenblatt, Kevin P., Baum, Michael G., Schiavi, Susan, Hu, Mei-Chang, Moe, Orson W., Kuro-o, Makoto", "journal": "Journal of Biological Chemistry", "year": "2007", "volumes": "282", "first page": "12305", "last page": "12313", "DOI": "10.1074/jbc.M700407200"}, {"title": "NASH CRN, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial", "authors": "Harrison, Stephen A., Abdelmalek, Manal F., Caldwell, Stephen, Shiffman, Mitchell L., Diehl, Anna Mae, Ghalib, Reem, Lawitz, Eric J., Rockey, Don C., Schall, Robert A., Younes, Ziad H., Sanyal, Arun J.", "journal": "The Lancet", "year": "2018", "volumes": "391", "first page": "1174", "last page": "1185", "DOI": "10.1016/S0140-6736(18)30474-4"}, {"title": "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial", "authors": "Sanyal, Arun J., Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen, Shiffman, Mitchell L., Ghalib, Reem, Lawitz, Eric J., Rockey, Don C.", "journal": "Hepatology", "year": "2019", "volumes": "69", "first page": "2411", "last page": "2421", "DOI": "10.1002/hep.30480"}, {"title": "The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes", "authors": "Gaich, Gerald, Chien, Jenny Y., Fu, Haiyan, Glass, Leonard C., Deeg, Mark A., Holland, William L., Kharitonenkov, Alexei, Bumol, Thomas, Schilske, Heidi K., Moller, David E.", "journal": "Cell Metabolism", "year": "2013", "volumes": "18", "first page": "333", "last page": "340", "DOI": "10.1016/j.cmet.2013.08.005"}, {"title": "FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents", "authors": "Charles, Eric D., Neuschwander-Tetri, Brent A., Frias, Juan P., Kundu, Ramendra K., Luo, Xiaoping, Tirucherai, Giridhar S., Christian, Renee, Wang, Minghan, Talukdar, Saswata", "journal": "Diabetes", "year": "2019", "volumes": "68", "first page": "143", "last page": "151", "DOI": "10.2337/db18-0682"}, {"title": "FGF21 requires βklotho to act in vivo", "authors": "Adams, Andrew C., Coskun, Tamer, Rovira, Albert R., Schneider, Michael A., Raches, David W., Micanovic, Radmila, Bina, Holly A., Kharitonenkov, Alexei", "journal": "PLoS One", "year": "2012", "volumes": "7", "first page": "e49977", "last page": "", "DOI": "10.1371/journal.pone.0049977"}, {"title": "FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis", "authors": "Talukdar, Saswata, Owen, Bryn M., Song, Parkyong, Hernandez, Genaro, Zhang, Youyou, Zhou, Yingjiang, Scott, William T., Paratala, Bhavna, Turner, Tiffany, Smith, Andrew, Bernardo, Barbara, Müller, Christoph P., Tang, Huaping, Mangelsdorf, David J., Goodwin, Bryan, Kliewer, Steven A.", "journal": "Genes & Development", "year": "2016", "volumes": "30", "first page": "1434", "last page": "1446", "DOI": "10.1101/gad.275859.115"}, {"title": "FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation", "authors": "Wu, Xianai, Ge, Hui, Lemon, Bryan, Vonderfecht, Steven, Weiszmann, Jennifer, Hecht, Randy, Gupte, Jamila, Hager, Thomas, Wang, Zhulun, Lindberg, Richard, Li, Yang", "journal": "Journal of Biological Chemistry", "year": "2011", "volumes": "286", "first page": "26635", "last page": "26643", "DOI": "10.1074/jbc.M111.241323"}, {"title": "FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents", "authors": "Foltz, Ian N., Hu, Shihua, King, Christopher, Wu, Xianai, Yang, Chun, Wang, Weimin, Weiszmann, Jennifer, Stevens, Jennitte, Chen, Jie, Nuanmanee, Nuanchan, Komorowski, Renee, Veniant, Murielle M., Li, Yang S., Lindberg, Richard, Li, Yang", "journal": "Diabetes", "year": "2012", "volumes": "61", "first page": "505", "last page": "512", "DOI": "10.2337/db11-0838"}]}